GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Milei Threatens Falkland Oil Firms With Sanctions 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Xiaomi Shares Jump on Europe EV Expansion Plan 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Add as a preferred source on Google
CHESTERBROOK, Pa., March 07, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Cowen and Company 38th Annual Healthcare Conference on Wednesday, March 14, 2018, at 8:40 a.m. ET in Boston, MA.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product OLINVO™ (oliceridine) Injection for the management of moderate-to-severe acute pain. OLINVO has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
